ReviewJournal of hepatocellular carcinoma2026
Decoding Treatment Response in Hepatocellular Carcinoma: The Era of Radiomics and Radiogenomics.
Review in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) immunotherapy is significantly constrained by a low objective response rate (~30%) and the lack of universally applicable predictive biomarkers. Radiomics, a non-invasive technique that extracts high-throughput hidden features from medical images, offers innovative solutions for patient selection, treatment response assessment, and prognosis prediction. This review systematically summarizes the application scenarios, feature extraction, and model construction of multimodal imaging data in HCC immunotherapy. It highlights advances in radiomics for predicting treatment response and evaluating the tumor immune microenvironment (TIME) and underlying molecular signatures. It also analyzes key challenges, including limited sample sizes and poor model generalization, and outlines future directions such as multicenter standardized studies and multi-omics integration. The goal is to inform the clinical translation of radiomics for precision management of HCC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.